United States Embolic Protection Device Market is expected to reach US$ 650 million by 2033 from US$ 360 million in 2024, with a CAGR of 6.96% from 2025 to 2033. Rising cardiovascular operations, ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — In PROTECTED TAVR, the largest-ever randomized trial of transcatheter aortic valve replacement, ...

US hospitals pulled back on their use of cerebral embolic protection during TAVI after publication of the PROTECTED TAVR results, a new analysis affirms. The proportion of procedures done with the ...

Transcatheter aortic valve replacement (TAVR) is revolutionizing the treatment of aortic valve stenosis, offering a minimally invasive option for patients suffering from this heart condition. However, ...

Please provide your email address to receive an email when new articles are posted on . Adults who underwent transcatheter aortic valve replacement with a cerebral protection system experienced fewer ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

EmStop has completed the ‘Controlled Arterial Protection to Ultimately Remove Embolic Material’ (CAPTURE-1) early feasibility clinical study which assessed the EmStop embolic protection system. The ...

PARIS, France—A new analysis of more than 10,000 patients likely slams the door on routinely using cerebral embolic protection for stroke prevention in patients with aortic stenosis undergoing TAVI.

Transcatheter aortic-valve replacement (TAVR) for the treatment of aortic stenosis can lead to embolization of debris. Capture of debris by devices that provide cerebral embolic protection (CEP) may ...